Skip to content
Advertisement

A bottle containing the drug Remdesivir is held by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary, Thursday Oct. 15, 2020. A large study led by the World Health Organization released on Friday, Oct. 16, 2020, suggests that the antiviral drug did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries. The results do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival. (Zsolt Czegledi/MTI via AP)
Photo by: Zsolt Czegledi
A bottle containing the drug Remdesivir is held by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary, Thursday Oct. 15, 2020. A large study led by the World Health Organization released on Friday, Oct. 16, 2020, suggests that the antiviral drug did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries. The results do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival. (Zsolt Czegledi/MTI via AP)

Featured Photo Galleries